- Details
- Charles Drake presented on immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) during the Management of Castration-resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He reviews several immunotherapy trials including the first major successful trial in immunotherapy for prostate cancer, the IMPACT trial in 2010 which led...
|
- Details
- Fernando Maluf joins Charles Ryan to discuss the data from the first Prostate Cancer Global Consensus Conference for Developing Countries. This was a tremendous achievement in which more than a hundred physicians from all over the world, particularly from developing countries in Latin America, Africa, and the Middle East participated. Physicians that participated included several specialties: urol...
|
- Details
- Alicia Morgans and Brad McGregor discuss rare genitourinary histologies and the efforts to find treatment options for populations not always included in clinical trials. Most clinical trials are developed and designed for the most common subtypes, not including atypical variant histologies often found in bladder and prostate cancers. Given the tumor agnostic approach of immunotherapy, Brad and his...
|
- Details
- Thomas Steuber spoke on the role of surgery in the setting of metastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He highlights the advantages of surgical removal of the primary tumor, the effects of surgery on cancer-specific survival and overall survival compared with no local treatment in the setting of de novo metastatic prostate cancer, and prospectiv...
|
- Details
- In this presentation by Fernando Maluf at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) he summarizes the results of the first Latin American Oncology Group (LACOG) consensus conference, a Cooperative Group Consensus that takes place in Brazil, a consensus conference for developing countries. This unique conference provided guidelines for prostate cancer, specifically for areas of...
|
- Details
- David Wise discusses his work studying the role of DKK1 as a driver of some forms of CRPC with Charles Ryan. He describes that the role of immune checkpoint inhibitors in prostate cancer has been largely disappointing. Dr. Wise shares his previous findings that DKK1 is upregulated in a subset of metastatic CRPC with low or no expression of AR and that do not have features of neuroendocrine or smal...
|
- Details
- Susan Halabi provides an update on an externally validated prognostic model of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, which included eight important prognostic factors variables of overall survival: opioid analgesic use, ECOG performance status, albumin, disease site, LDH, hemoglobin, PSA, and alkaline phosphatase. They use...
|
- Details
- Oliver Sartor joins Charles Ryan in a discussion on a Phase 4 registry trial in men with metastatic castration-resistant prostate cancer (mCRPC). The IMPACT study analyses suggested that overall survival (OS) was longer in treated and control patients with low baseline PSA, and OS benefit was greatest for sipuleucel-T versus control in the patients with the lowest PSA (Schellhammer Urol 2013). Eli...
|
- Details
- Phillip Koo joins Neal Shore to discuss radium 223 for treating men with metastatic castration-resistant prostate cancer. Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). The survival benefit and the safety and tolerability profile of radium-223...
|
- Details
- Sipuleucel-T (Provenge ® ) has been FDA approved since 2010 in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). The IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment), was a randomized, double-blind, placebo-controlled study of 512 men with metastatic, hormone-refractory prostate cancer. Initially, the targeted patients were those wi...
|
